Olfr582 Inhibitors
Olfr582, a member of the olfactory receptor family, plays a crucial role in the complex process of olfactory signal transduction. Situated in the sensory neurons of the olfactory epithelium, Olfr582 functions as a molecular detector for specific odorants. Its primary responsibility lies in the recognition and transmission of olfactory stimuli, initiating a cascade of intracellular events that eventually lead to the perception of distinct smells. The activation of Olfr582 triggers a series of molecular events, ultimately resulting in the generation of neural signals that are transmitted to the brain, contributing to the intricate and nuanced process of odor perception.
The inhibition of Olfr582 involves a sophisticated interplay of various cellular pathways that influence its expression. Indirect inhibitors modulate key signaling cascades such as the EGFR, MAPK, TGF-β, PI3K/Akt/mTOR, NF-κB, and JNK pathways. These inhibitors exert their effects at different points in these pathways, leading to altered cellular responses that impact Olfr582 expression. Whether through disrupting the MEK-ERK signaling axis, attenuating downstream Smad signaling, or inhibiting NF-κB activation, the overarching goal is to influence the intricate web of molecular events associated with olfactory signal transduction. This intricate modulation showcases the complexity of Olfr582 regulation and highlights the need for a comprehensive understanding of the interplay between these signaling pathways to effectively modulate the expression of this olfactory receptor. Overall, Olfr582's significance in olfactory perception and the detailed mechanisms of its inhibition underscore the intricate nature of molecular events that govern sensory processes in the olfactory system.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Gefitinib | 184475-35-2 | sc-202166 sc-202166A sc-202166B sc-202166C | 100 mg 250 mg 1 g 5 g | $63.00 $114.00 $218.00 $349.00 | 74 | |
Gefitinib inhibits the EGFR signaling pathway, indirectly downregulating Olfr582 expression. By disrupting key components of this pathway, it influences downstream cascades, leading to modified gene expression patterns of Olfr582. | ||||||
Trametinib | 871700-17-3 | sc-364639 sc-364639A sc-364639B | 5 mg 10 mg 1 g | $114.00 $166.00 $947.00 | 19 | |
Trametinib, a MEK inhibitor, indirectly influences Olfr582 by targeting the MAPK pathway. This disruption alters the ERK signaling cascade, resulting in indirect downregulation of Olfr582 expression through interference with its associated molecular pathways. | ||||||
SB 431542 | 301836-41-9 | sc-204265 sc-204265A sc-204265B | 1 mg 10 mg 25 mg | $82.00 $216.00 $416.00 | 48 | |
SB-431542 functions as a TGF-β receptor inhibitor, attenuating downstream Smad signaling. This indirect inhibition of Olfr582 occurs by interfering with the TGF-β pathway, leading to modified cellular responses and reduced expression of the target gene. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin, a PI3K inhibitor, indirectly regulates Olfr582 by disrupting the PI3K/Akt pathway. This leads to modified intracellular signaling, impacting Olfr582 expression through interference with the associated molecular cascades and downstream effectors. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059, a MEK inhibitor, indirectly inhibits Olfr582 by disrupting the MAPK pathway. Through the inhibition of MEK, PD98059 alters the ERK signaling cascade, resulting in indirect downregulation of Olfr582 expression by interfering with its associated molecular pathways. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin, an mTOR inhibitor, indirectly influences Olfr582 by modulating the mTOR signaling pathway. This indirect inhibition leads to altered cellular responses, affecting Olfr582 expression through disruptions in the associated molecular cascades and downstream targets. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002, a PI3K inhibitor, indirectly influences Olfr582 by modulating the PI3K/Akt/mTOR pathway. This inhibition results in altered intracellular signaling, impacting Olfr582 expression through disruptions in the associated molecular cascades and downstream effectors. | ||||||
AZD5363 | 1143532-39-1 | sc-503190 | 5 mg | $309.00 | ||
AZD5363, an Akt inhibitor, indirectly inhibits Olfr582 by targeting the PI3K/Akt/mTOR pathway. This inhibition results in altered intracellular signaling, impacting Olfr582 expression through disruptions in the associated molecular cascades and downstream effectors. | ||||||
BAY 11-7082 | 19542-67-7 | sc-200615B sc-200615 sc-200615A | 5 mg 10 mg 50 mg | $62.00 $85.00 $356.00 | 155 | |
BAY 11-7082, an NF-κB inhibitor, indirectly inhibits Olfr582 by modulating the NF-κB signaling pathway. This leads to altered cellular responses, affecting Olfr582 expression through disruptions in the associated molecular cascades and downstream targets. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $57.00 $100.00 $250.00 | 129 | |
Sorafenib acts as a multikinase inhibitor, impacting the Ras/Raf/MEK/ERK pathway. By disrupting this pathway, Olfr582 expression is indirectly downregulated. The inhibition is mediated through interference with key signaling molecules in the mentioned pathway. | ||||||